DNA Repair and Genetic Susceptibility to Lung Cancer

Study summary

The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final. We will analyze your blood cells and DNA to measure the changes in several genes that we believe may be involved in lung cancer. We also want to evaluate the capacity for your DNA to repair itself.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood draw and Questionnaires and Blood draw and Questionnaires

The study team can explain what participation involves.

Who it may be forLung Cancer · Single Primary Lung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 29, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Other: Blood draw and Questionnaires; Other: Blood draw and Questionnaires

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Cases will be eligible for inclusion if:
They have been diagnosed with a second primary lung cancer, and
They speak English or a language for which we have a translated consent form, and
They understand and agree to sign informed consent, and
They agree to give us a blood sample, and
They agree to give us a tissue sample when part of normal clinical procedures, and
They agree to complete the study questionnaires, and
They agree to have their pathology information reviewed. This could include biopsy specimens. Controls will be eligible for inclusion if
They have been diagnosed with a first primary lung cancer, and
They speak English or a language for which we have a translated consent form, and
They understand and agree to sign informed consent, and
They agree to give us a blood sample, and
They agree to give us a tissue sample when part of normal clinical procedures, and
They agree to complete the study questionnaires,
They agree to have their pathology information reviewed. This will could include biopsy specimens.

Reasons someone may not be able to joinExclusion criteria

Subjects who do not meet the inclusion criteria as either cases or controls will not be eligible for this study.
Control subjects who have a history of another cancer, other than nonmelanoma skin cancer or a first primary lung cancer, will not be eligible for this study.
Control subjects who otherwise meet the eligibility requirements above but who have had chemotherapy and/or are currently being treated with chemotherapy will be excluded from the functional assay, but not from the genotyping.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 29, 2023. Always confirm current availability with the study team.

View original record ↗